1. Home
  2. MRK
  3. MRK News

Latest Merck & Company Inc. (new) (MRK) News on November 2, 2025

Alternative Economic Data Point to Solid Growth
MRK

Barrons.com

a day ago

Alternative Economic Data Point to Solid Growth

The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot
MRK

PR Newswire

2 days ago

The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot

MRK

MT Newswires

2 days ago

Morgan Stanley Adjusts Price Target on Merck & Co. to $100 From $98

Merck Q3 2025 Earnings Call Transcript
MRK

Motley Fool

2 days ago

Merck Q3 2025 Earnings Call Transcript

MRK

MT Newswires

2 days ago

Goldman Sachs Adjusts Price Target on Merck & Co to $92 From $93

MRK

Morningstar Research

2 days ago

Analyst Report: Merck & Co., Inc.

Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' quarter; Exxon, Chevron post strong earnings
MRK

Yahoo Finance

2 days ago

Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' quarter; Exxon, Chevron post strong earnings

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
MRK

GlobeNewswire

2 days ago

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Merck (MRK) Margin Expansion Tops Narratives With 19.4% EPS Growth and 25.8% Profit Margin
MRK

Simply Wall St.

2 days ago

Merck (MRK) Margin Expansion Tops Narratives With 19.4% EPS Growth and 25.8% Profit Margin

Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' holiday quarter, Reddit and Coinbase rise
MRK

Yahoo Finance

2 days ago

Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' holiday quarter, Reddit and Coinbase rise

Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle
MRK

The Wall Street Journal

2 days ago

Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle

Merck & Co Inc (MRK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
MRK

GuruFocus.com

2 days ago

Merck & Co Inc (MRK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges

Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain
MRK

Investor's Business Daily

2 days ago

Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain

MRK

Investing.com

3 days ago

Moderna stock soars after report of potential buyout talks

Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson
MRK

GlobeNewswire

3 days ago

Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson

MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
MRK

Zacks

3 days ago

MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down

Merck Stock Falls. Sales of Key Products Missed Estimates.
MRK

Barrons.com

3 days ago

Merck Stock Falls. Sales of Key Products Missed Estimates.

Apple & Amazon earnings, Fed, mortgage rates: What to Watch
MRK

Yahoo Finance Video

3 days ago

Apple & Amazon earnings, Fed, mortgage rates: What to Watch

Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet rises as Big Tech earnings pour in
MRK

Yahoo Finance

3 days ago

Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet rises as Big Tech earnings pour in

Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.
MRK

Barrons.com

3 days ago

Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.

MRK

MT Newswires

4 days ago

Merck's Keytruda Wins EU Approval for First-Line Head and Neck Cancer Regimen

MRK

MT Newswires

4 days ago

Merck, Esai Close Phase 3 Liver Cancer Trial After Missing Overall Survival Endpoint

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
MRK

Zacks

4 days ago

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
MRK

Business Wire

4 days ago

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
MRK

Business Wire

4 days ago

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Earnings live: Wayfair stock soars following Q3 results, PayPal rises, Royal Caribbean slides
MRK

Yahoo Finance

4 days ago

Earnings live: Wayfair stock soars following Q3 results, PayPal rises, Royal Caribbean slides

Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
MRK

Zacks

5 days ago

Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know

3 Cancer-Focused Stocks Showing Strong Pipeline Progress
MRK

Zacks

5 days ago

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain
MRK

24/7 Wall St.

5 days ago

As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain

MRK

MT Newswires

5 days ago

Merck, Eisai Cancer Drug Combination Meets One Primary Endpoint in Late-Stage Trial

MRK

MT Newswires

5 days ago

Merck Says Phase 3 Study of Keytruda, Welireg to Treat Kidney Cancer Met Primary Endpoint

Merck kidney cancer drug succeeds in two large trials
MRK

BioPharma Dive

5 days ago

Merck kidney cancer drug succeeds in two large trials

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
MRK

GlobeNewswire

5 days ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Earnings live: Keurig Dr. Pepper stock pops, Waste Management and Whirlpool slip with Big Tech results on deck
MRK

Yahoo Finance

5 days ago

Earnings live: Keurig Dr. Pepper stock pops, Waste Management and Whirlpool slip with Big Tech results on deck

3 Dividend-Paying Drug Stocks to Buy at a Discount
MRK

Motley Fool

6 days ago

3 Dividend-Paying Drug Stocks to Buy at a Discount

Are You Looking for a High-Growth Dividend Stock?
MRK

Zacks

6 days ago

Are You Looking for a High-Growth Dividend Stock?

Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
MRK

Zacks

6 days ago

Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues

What's in Store for These 5 Pharma Bigwigs This Earnings Season?
MRK

Zacks

6 days ago

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

3 Healthcare Stocks to Buy Hand Over Fist in October
MRK

Motley Fool

6 days ago

3 Healthcare Stocks to Buy Hand Over Fist in October

JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
MRK

Zacks

6 days ago

JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?

Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
MRK

Zacks

6 days ago

Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data
MRK

Insider Monkey

7 days ago

Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data

Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch
MRK

Yahoo Finance Video

8 days ago

Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch

Merck's Non-Oncology Drugs Q3 Performance: What to Expect
MRK

Zacks

9 days ago

Merck's Non-Oncology Drugs Q3 Performance: What to Expect

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
MRK

Zacks

9 days ago

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

United States Lipid Nanoparticle Market Forecast and Competitive Analysis Report 2025-2033 Featuring Merck, Evonik, Genevant Sciences, CordenPharma, Arcturus, Ascendia, Acuitas, Croda
MRK

GlobeNewswire

9 days ago

United States Lipid Nanoparticle Market Forecast and Competitive Analysis Report 2025-2033 Featuring Merck, Evonik, Genevant Sciences, CordenPharma, Arcturus, Ascendia, Acuitas, Croda

eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
MRK

PR Newswire

10 days ago

eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience

Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
MRK

Zacks

10 days ago

Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Trump's Next Shock Move: U.S. Weighs Software Ban That Could Hit China's Tech Core
MRK

GuruFocus.com

10 days ago

Trump's Next Shock Move: U.S. Weighs Software Ban That Could Hit China's Tech Core

MRK

Business Wire

10 days ago

Net Asset Value(s)

MRK

MT Newswires

10 days ago

NioCorp, Lockheed Martin Collaborate on Scandium-Based Defense Technology

MRK

MT Newswires

10 days ago

BofA Securities Adjusts Price Target on NVR to $9,200 From $9,000, Maintains Buy Rating

MRK

MT Newswires

10 days ago

BofA Securities Adjusts Bumble Price Target to $5 From $5.50, Maintains Underperform Rating

MRK

MT Newswires

10 days ago

BofA Ups Price Target on International Business Machines to $315 From $310, Reports Solid 3Q; Maintains Buy Rating

MRK

MT Newswires

10 days ago

BofA Securities Adjusts Duolingo Price Target to $370 From $450, Maintains Neutral Rating

MRK

MT Newswires

10 days ago

BofA Raises Price Target on AeroVironment to $450 From $300 on Strong Product Demos, Maintains Buy Rating

Jim Cramer Says “Danaher Gave Us the Quarter We’ve Been Looking For”
MRK

Insider Monkey

10 days ago

Jim Cramer Says “Danaher Gave Us the Quarter We’ve Been Looking For”

MRK

MT Newswires

10 days ago

Merck Says FDA Granted Priority Review on Keytruda, Keytruda Qlex Applications for Bladder Cancer

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
MRK

Business Wire

10 days ago

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
MRK

Business Wire

10 days ago

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

Merck (MRK): Valuation Perspective as Groundbreaking Cancer Trial Wins Drive New Investor Focus
MRK

Simply Wall St.

11 days ago

Merck (MRK): Valuation Perspective as Groundbreaking Cancer Trial Wins Drive New Investor Focus

United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt
MRK

GlobeNewswire

12 days ago

United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt

MSD initiates construction on $3bn Virginia drug manufacturing site
MRK

Pharmaceutical Technology

12 days ago

MSD initiates construction on $3bn Virginia drug manufacturing site

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
MRK

GlobeNewswire

12 days ago

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
MRK

Business Wire

12 days ago

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
MRK

GlobeNewswire

12 days ago

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Merck (MRK) Outpaces Stock Market Gains: What You Should Know
MRK

Zacks

12 days ago

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

MRK

MT Newswires

12 days ago

Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint

MRK

MT Newswires

12 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
MRK

ACCESS Newswire

13 days ago

Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
MRK

GlobeNewswire

13 days ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
MRK

Business Wire

14 days ago

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
MRK

Business Wire

15 days ago

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
MRK

Investor's Business Daily

15 days ago

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
MRK

Business Wire

15 days ago

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
MRK

Business Wire

15 days ago

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
MRK

Zacks

16 days ago

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?

Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating
MRK

Insider Monkey

16 days ago

Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating

Trump Strikes Deal With Merck KGaA on Tariffs, IVF Costs
MRK

Bloomberg

16 days ago

Trump Strikes Deal With Merck KGaA on Tariffs, IVF Costs

EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
MRK

Business Wire

16 days ago

EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies

2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off
MRK

StockStory

17 days ago

2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
MRK

Zacks

17 days ago

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

MRK

MT Newswires

17 days ago

Merck Says Keytruda With Chemotherapy Phase 3 Ovarian Cancer Trial Meets Secondary Endpoint

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
MRK

Business Wire

17 days ago

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength
MRK

Insider Monkey

17 days ago

Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength

Germany’s Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets
MRK

The Wall Street Journal

17 days ago

Germany’s Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets

1 Profitable Stock Worth Your Attention and 2 Facing Challenges
MRK

StockStory

17 days ago

1 Profitable Stock Worth Your Attention and 2 Facing Challenges

Why Moderna Might Be a One-Hit Wonder
MRK

Motley Fool

17 days ago

Why Moderna Might Be a One-Hit Wonder

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations
MRK

GlobeNewswire

18 days ago

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations

MRK

MT Newswires

18 days ago

Merck Says Data From Late-Stage Studies Show Investigational Two-Drug HiV Therapy Maintains Viral Suppression

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships
MRK

GlobeNewswire

18 days ago

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
MRK

Business Wire

18 days ago

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck (MRK) Declines More Than Market: Some Information for Investors
MRK

Zacks

18 days ago

Merck (MRK) Declines More Than Market: Some Information for Investors

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
MRK

Zacks

19 days ago

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
MRK

Motley Fool

19 days ago

Can $10,000 in Merck Stock Turn Into $50,000 by 2030?

Merck & Co. Earnings Preview: What to Expect
MRK

Barchart

19 days ago

Merck & Co. Earnings Preview: What to Expect

Top Stock Reports for Apple, Eli Lilly & Visa
MRK

Zacks

19 days ago

Top Stock Reports for Apple, Eli Lilly & Visa

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
MRK

StockStory

20 days ago

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

Moderna (MRNA) Stock Trades Up, Here Is Why
MRK

StockStory

20 days ago

Moderna (MRNA) Stock Trades Up, Here Is Why

How Keytruda’s Subcutaneous FDA Approval and Extended Patent Could Shape Merck’s (MRK) Investment Trajectory
MRK

Simply Wall St.

20 days ago

How Keytruda’s Subcutaneous FDA Approval and Extended Patent Could Shape Merck’s (MRK) Investment Trajectory

Share on Social Networks: